Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone vs Docetaxel in Advanced Breast Cancer
NCT05430399Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of utidelone in breast cancer, sponsored by Sun Yat-sen University. Started Jun 2022; status: recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05430399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430399.